Wire · opportunities
GSK Eyes FDA Filing After Immunotherapy Succeeds in Key Rectal Cancer Study
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 July 2026 · Fusion42 review
GSK's dostarlimab (Jemperli) met primary endpoints in a Phase 2 trial for dMMR rectal cancer, showing sustained complete responses at 12 months and enabling patients to avoid surgery, chemotherapy, and radiation. The company plans FDA filing with expedited review under the National Priority Review Voucher programme.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're building surgical robotics or rectal cancer diagnostics for traditional pre-operative staging, your market just shrank. GSK's drug now offers a curative path that skips the operating theatre entirely for a defined patient cohort—and has FDA fast-track approval.
◆ Coverage
1 source · 14 Jul 2026
◆ Related on Wire
◆ Topics